RxDoctor Payments Data

Gary Hardoon, MD

Internal Medicine · Palm Bay, FLNPI 1558637686

Payments from drug & device makers

$1,215in general payments, 2019–2025

Across 54 payments — averaging $22.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$277
  • Johnson & Johnson$170
  • Abbott$159
  • AstraZeneca$148
  • Astellas Pharma US Inc$125
  • Lilly USA, LLC$103
  • plus $233 from 11 others

What the payments were for

  • Food & beverage$1,13093%
  • Education$857%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,215 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$295,426
Medicare patients
401
Services billed
4,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin94$120,481
OzempicSemaglutide70$83,790
EliquisApixaban53$54,836
JanuviaSitagliptin Phosphate33$42,627
XifaxanRifaximin11$34,183
MounjaroTirzepatide36$33,335
TrulicityDulaglutide12$23,733
Tresiba Flextouch U-200Insulin Degludec12$17,942
XareltoRivaroxaban16$12,985
Tresiba Flextouch U-100Insulin Degludec20$7,061
Sumatriptan Succinate18$5,940
Rosuvastatin Calcium232$5,572
Atorvastatin Calcium340$5,042
Levothyroxine Sodium232$3,479
Nebivolol Hcl51$3,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$17$120,48194 claims
Novo NordiskOzempic$277$83,79070 claims
Lilly USA, LLCMounjaro, Trulicity$103$57,06848 claims
PfizerEliquis$37$54,83653 claims
MerckJanuvia$11$42,62733 claims
Johnson & JohnsonXarelto$170$12,98516 claims
AbbVieSynthroid$46$2,64642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Palm Bay

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →